Skip to main content
SpringerLink
Log in
Book cover

Kidney Cancer pp 155–172Cite as

Interleukin-2 Based Therapy for Kidney Cancer

  • Chapter

Part of the book series: Cancer Treatment and Research ((CTAR,volume 116))

Abstract

Interleukin-2 (IL-2) is a 15 kDa glycoprotein, originally characterized as T-cell growth factor,’ and is produced in response to T-cell activation. Interleukin-2 binds to cells through T-cell receptors which are up-regulated with activation, and through these receptors, signals clonal expansion of T-cells, with specific and non-specific immunity, and expansion of natural killer (NK) cells, all with cytotoxic activity.2In addition, secondary cytokines are released, such as interferon-gamma, tumor necrosis factor, and interleukin-1, among others.’ Recombinant DNA technology has allowed the production of IL-2 in large quantities, allowing for clinical investigation of this agent.’ The most generally used formulation is that produced by Chiron, Proleukin®. Subsequent to this, clinical trials have demonstrated efficacy in the treatment of metastatic renal cell cancer and melanoma, and IL-2 was approved for these indications. The initial approval was for therapy with high dose IL-2, to be described below, which remains the gold standard for IL-2 administration in renal cell causes and melanoma. This approval is based on the durability of the responses that are produced. However, due to the toxicity and the need for patient selectivity with high dose IL-2, a variety of regimens exploring lower doses and different schedules and combinations have been investigated. These will be summarized.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Morgan, DA, Ruscetti FW, Gallo R: Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 1976; 192:1007–1009.

    Article  Google Scholar 

  2. Baker PE, Gillis S, Ferm MM, Smith KA: The effect of T-cell growth factor on the generation of cytolytic T-cells. J Immunol 1978; 121:2168–2172.

    PubMed  CAS  Google Scholar 

  3. Mier J, Vachino G, Vander Meer J, et al: Induction of circulating tumor necrosis factor as the mechanism for the febrile response to interleukin-2.JClin Immunol 1988; 8:426–431.

    Article  PubMed  CAS  Google Scholar 

  4. Taniguchi T, Matsui H, Fujita T, et al: Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983; 302:305–310.

    Article  PubMed  CAS  Google Scholar 

  5. Mule JJ, Shu S, Schwarz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225:1487–1489.

    Article  PubMed  CAS  Google Scholar 

  6. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N EnglJMed 1985; 313:1485–1492.

    Article  PubMed  CAS  Google Scholar 

  7. West WH, Tauer KW, Yanelli JR, et al: Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N EnglJMed 1987; 316:898–905.

    Article  PubMed  CAS  Google Scholar 

  8. Fisher RI, Coltman CA, DoroshowJHet al: Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1988; 108:518–523.

    PubMed  CAS  Google Scholar 

  9. McCabe MS, Stablein D, Hawkins MJ: The modified Group C experience-Phase III randomized trials of IL-2 vs IL-2/LAK in advanced renal cell carcinoma and advanced melanoma. Proc Am Soc Clin Oncol 1991; 10:213 (abst).

    Google Scholar 

  10. Abrams JS, Raynor AA, Wiernik PH, et al: High dose recombinant interleukin-2 alone: A regimen with limited activity in the treatment of advanced renal cell carcinoma. N Jatl Cancer Insti 1990; 82:1202–1206.

    Article  CAS  Google Scholar 

  11. Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.JNatl Cancer Inst 1993; 85:622–632.

    Article  PubMed  CAS  Google Scholar 

  12. Rosenberg SA, Lotze MT, Yang JC, et al: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210:474–485.

    Article  PubMed  CAS  Google Scholar 

  13. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment with 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.JClin Oncol 1995; 13: 688–696.

    PubMed  CAS  Google Scholar 

  14. Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G: High does Aldesleukin in renal cell carcinoma: Long-term survival update. CancerJSci Amer 1997; 3(Supple 1):52–54.

    Google Scholar 

  15. Yang JC, Topalian SL, Parkinson D, et al: Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report.JClin Oncol 1994; 12:1572–1576.

    PubMed  CAS  Google Scholar 

  16. Yang JC, Rosenberg SA: An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. CancerJSci Amer 1997; 3:S79–S84.

    Google Scholar 

  17. Gitlitz BJ, Hoffman DM, Moldawer N, et al: Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients. Cancer j Sci Am 2001: 7:112–120.

    CAS  Google Scholar 

  18. Atkins MB, Sparano J, Fisher RI, et al: Randomized phase II trial of high dose IL-2 either alone or in combination with interferon alfa 2b in advanced renal cell carcinoma.JClin Oncol 1993; 11: 661–670.

    PubMed  CAS  Google Scholar 

  19. McDermott D, Flaherty L, Clark J, et al: A randomized phase III trial of high-dose interleukin-2 versus subcutaneous IL2/Interferon in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2001; 20:172a.

    Google Scholar 

  20. Weiss GR, Margolin KA, Aronson FR, et al: A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.JClin Oncol 1992; 10:275–281.

    PubMed  CAS  Google Scholar 

  21. Negrier S, Philip T, Stoter G, et al: Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: A report of a European multicentre study. Eur J Cancer Clin Oncol 1989; 25 (Suppl 3): S21–S28.

    PubMed  Google Scholar 

  22. Shulman KL, Stadler WM„ Vogelzang NJ: High dose continuous intravenous infusion of interleukin2 therapy for metastatic renal cell carcinoma: the University of Chicago experience. Urology 1996; 47:194–197.

    Article  PubMed  CAS  Google Scholar 

  23. Escudier B, Ravaud A, Fabbro M, et al: High-dose interleukin-2 two days a week for metastatic renal cell carcinoma: A FNCLCC multicenter study. J Immunother Emphasis Tumor Immunol 1994; 15:306–312.

    Article  Google Scholar 

  24. Iigo M, Sakurai M, Tamura T et al: In vivo anti-tumor activity of multiple injections of recombinant interleukin-2 alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res 1988; 48:260–264.

    PubMed  CAS  Google Scholar 

  25. Brunda MJ, Bellantoni D, Sulich V: In vivo anti-tumor activity of combinations of interferon-alpha and interleukin-2 in a murine model: Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 1987; 40:365–371.

    Article  PubMed  CAS  Google Scholar 

  26. Cameron RB, McIntosh JK, Rosenberg SA: Synergistic anti-tumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res 1988; 48:5810–5817.

    PubMed  CAS  Google Scholar 

  27. Weber JS, Rosenberg SA: Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res 1988; 48:5818–5824.

    PubMed  CAS  Google Scholar 

  28. Guadagni F, Schlom J, Johnston WW, et al: Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst 1989; 81:502–511.

    Article  PubMed  CAS  Google Scholar 

  29. Rosenberg SA, Lotze MT, Yang JC, et al: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7:1863–1874.

    PubMed  CAS  Google Scholar 

  30. Marincola FM, White DE, Wise AP, Rosenberg SA: Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995; 13:1110–1122.

    PubMed  CAS  Google Scholar 

  31. Aronson FR, Sznol M, Atkins MB, et al: A phase II trial of interleukin-2, interferon-alpha, and lymphokine activated killer cells for advanced renal cell carcinoma. Proc Am Soc Clin Oncol 1990; 9: 182.

    Google Scholar 

  32. Sznol M, Mier J, Sparano J, et al: A phase I study of high dose interleukin-2 in combination with interferon-alfa 2B. J Biol Resp Modifers 1990; 9:529–537.

    CAS  Google Scholar 

  33. Atkins MB, Dutcher JP, Weiss G, et al: Kidney Cancer: The Cytokine Working Group Experience (1986–2001). Part I: IL-2 based clinical trials. Med Oncol 2001; 18:197–207.

    Article  PubMed  CAS  Google Scholar 

  34. Hirsch R, Eckhuar M, Auchincloss, et al: Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice: I. Immunosuppression or transplantation responses J Immunol 1988; 140:3766–3772.

    PubMed  CAS  Google Scholar 

  35. Hirsch R, Gress RE, Pluznik DH, et al: Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice: II. In vivo activation of T cells. J Immunol 1989; 142:737–740.

    PubMed  CAS  Google Scholar 

  36. Sosman JA, Weiss GR, margolin KA, et al: A phase IB clinical trial of anti-CD3 (OKT3) followed by high dose bolus IL-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunological effects. J Clin Oncol 1993; 11:1496–1505.

    PubMed  CAS  Google Scholar 

  37. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155:1823–1841.

    Article  PubMed  CAS  Google Scholar 

  38. Topalian SL, Solomon D, Avis FP, et al: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J Clin Oncol 1988; 6: 839–853.

    PubMed  CAS  Google Scholar 

  39. Figlin RA, Thompson JA, Bukowski RM, et al: Multicenter, randomized, phase III trial of CD8 (+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999; 17:2521–2529.

    PubMed  CAS  Google Scholar 

  40. Bukowski RM, Sharftnan W, Murthy S, et al: Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic renal cell carcinoma. Cancer Res 1991; 51:4199–4205.

    PubMed  CAS  Google Scholar 

  41. Rayman P, Uzzo RG, Kolenko V, et al: Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: A mechanism of immune escape. Cancer J Sci Amer 2000; 6 (Suppl 1): S81–S87.

    Google Scholar 

  42. Alexander JP, Kudoh S, Melsop KA et al: T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin-2 and express interleukin-2 receptors. Cancer Res 1993; 53:1380–1387.

    PubMed  CAS  Google Scholar 

  43. Miescher S, Stoeck M, Qiao L et al: Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int J Cancer 1988; 42:659–666.

    Article  PubMed  CAS  Google Scholar 

  44. Margolin KA, Rayner AA, Hawkins MJ, et al: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 1989; 4: 486–498.

    Google Scholar 

  45. Dutcher JP, Atkins MB, Margolin K, et al: Kidney Cancer: The Cytokine Working Group Experience (1986–2001). Part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol 2001; 18:209–219.

    Article  PubMed  CAS  Google Scholar 

  46. Kammula US, White DE, Rosenberg SA:Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998; 83:797–805.

    Article  PubMed  CAS  Google Scholar 

  47. Thompson JA, Shulman KL, Benyunes MC, et al: Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 1992; 10:960–968.

    PubMed  CAS  Google Scholar 

  48. Palmer PA, Atzpodien J, Philip T, et al: A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother 1993; 8:123–136.

    Article  PubMed  CAS  Google Scholar 

  49. Figlin RA, Belldegrun A, Moldawer N, et al: Concomitant administration of recombinant human interleukin-2 and recombinant interfreron alfa-2A: An active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992; 10:414–421.

    PubMed  CAS  Google Scholar 

  50. Ilson DH, Motzer RJ, Kradin RL, et al: A phase II trial of interleukin-2 and interferon-alfa-2a in patients with advanced renal cell carcinoma. J Clin Oncol 1992; 10:1124–1130.

    PubMed  CAS  Google Scholar 

  51. Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med 1998; 338:1272–1278.

    Article  PubMed  CAS  Google Scholar 

  52. Negrier S, Maral J, Drevon M, et al: Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Amer 2000; 6 (Suppl 1): S93–S98.

    Google Scholar 

  53. Kraden RL, Lazarus DS, Dubinette SM, et al: Tumor-infiltrating lymphocytes and interleukin-2 in treatement of advanced cancer. Lancet 1989; 1:577–580.

    Article  Google Scholar 

  54. Hayakawa K, Salmeron MA, Parkinson DA, et al: Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: Sequential proliferation of cytotoxic natural killer and non-cytotoxic T-cells in RCC. J Immunother 1991; 10:313–325.

    Article  PubMed  CAS  Google Scholar 

  55. Oldham RK, Dillman RO, Yannelli JR, et al: Continous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: A National Biotherapy Study Group Trial. Mol Biother 1991; 3:68–73.

    PubMed  CAS  Google Scholar 

  56. Figlin R, Gitlitz B, Franklin J, et al: Interleukin-2 based immunotherapy for the treatment of metastatic renal cell carcinoma: An analysis of 203 consecutively treated patients. Cancer J Sci Amer 1997; 3:S92–S97.

    Google Scholar 

  57. Bukowski RM, Sharfman W, Murthy S etal: Clinical results and characteristics of tumor-infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic renal cell carcinoma. Cancer Res 1991; 51:4199–4205.

    PubMed  CAS  Google Scholar 

  58. Bukowski RM, Goodman P, Crawford ED, et al: Phase II trial of high-dose intermittent interleukin2 in metastatic renal cell cancer: A Southwest Oncology Group Study. J Natl Cancer Inst 1990; 82:143–146.

    Article  PubMed  CAS  Google Scholar 

  59. Sleijfer DT, Jannsen RAJ, Buter J, et al: Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992; 10:1119–1123.

    PubMed  CAS  Google Scholar 

  60. Buter J, Sleijfer DT, vanderGraaf WTA, et al:A progress report on the outpatient treatment of patients with advanced renal carcinoma using subcutaneous recombinant interleukin-2. Semin Oncol 1993; 20:16–21.

    PubMed  CAS  Google Scholar 

  61. Vogelzang NJ, Lipton A, Figlin RA: Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial. J Clin Oncol 1993; 11:1809–1816.

    PubMed  CAS  Google Scholar 

  62. Atzpodien J, Korfer A, Franks C, et al: Home therapy with recombinant interleukin-2 and interferon cab in advanced human malignanices. Lancet 1990; 335:1509–1512.

    Article  PubMed  CAS  Google Scholar 

  63. Atzpodien J, Hanninen EL, Kirchner H, et al: Multi-institutional home therapy trial of recombinant human IL-2 and IFN-alpha-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 1995; 13:497–501.

    PubMed  CAS  Google Scholar 

  64. Dutcher JP, Fisher RI, Weiss G, et al: An outpatient regimen of subcutaneous interleukin-2 plus alpha-interferon in metastatic renal cell cancer. Proc Am Soc Clin Oncol 1993; 12:248.

    Google Scholar 

  65. Dutcher JP, Fisher R, Weiss G, et al: Outpatient subcutaneous interleukin-2 plus alpha-interferon in metastatic renal cell cancer: 3 year follow-up of the Cytokine Working Group study. Proc Am Soc Clin Oncol 1995; 14:332.

    Google Scholar 

  66. Dutcher JP, Fisher RI, Weiss G, et al: Outpatient subcutaneous interleukin-2 plus alpha-interferon in metastatic renal cell cancer: Five-year follow-up of the Cytokine Working Group study. Cancer J Sci Amer 1997; 3:157–162.

    CAS  Google Scholar 

  67. McDermott D, Flaherty L, Clark J, et al: A randomized phase III trial of high-dose interleukin-2 versus subcutaneous IL2/Interferon in patients with metastatic renal cell carcinoma. J Immunotherapy 2001; 24:S15.

    Google Scholar 

  68. Schwartz EL, Hoffman M, O’Connor C, Wadler S: Stimulation of 5-fluorouracil metabolic activation by interferon-a in human colon carcinoma cells. Biochem Biophys Res Commun 1991; 182:1232–1239.

    Article  Google Scholar 

  69. Marumo K, Oya M, Murai M: Biochemical modulation of 5-fluorouracil with murine interferona/13 against murine renal cell carcinoma. Int J Urol 1997; 4:163–168.

    Article  PubMed  CAS  Google Scholar 

  70. Hanninen EL, Poliwoda H, Atzpodien J: Interferon-a/5-fluorouracil: a novel outpatient chemo/Immunotherapy for progressive metastatic renal cell carcinoma. Cancer Biother 1995; 10: 21–24.

    Article  Google Scholar 

  71. Sparano JA, Dutcher JP, Wiernik PH, et al: A phase II trial of low-dose continuous infusion 5fluorouracil plus interferon-a in patients with advanced renal cell carcinoma. Proc Soc Biol Therapy 1993.

    Google Scholar 

  72. Gebrosky NP, Koukol S, Nseyo UO, et al: Treatment of renal cell carcinoma with 5-fluorouracil and a-interferon. Urology 1997; 50:863–868.

    Article  PubMed  CAS  Google Scholar 

  73. Elias L, Blumenstein BA, Kish J, et al: A phase II trial of interferon-a and 5-fluorouracil in pateints with advanced renal cell carcinoma. A Southwest Oncology Group study. Cancer 1996; 78: 1085–1088.

    Article  PubMed  CAS  Google Scholar 

  74. Hofmockel G, Langer W, Theiss M, et al: Immunochemotherapy for metsatatic renal cell carcinoma using a regimen of interleukin-2, interferon-a, and 5-fluorouracil. J Urol 1996; 156:18–21.

    Article  PubMed  CAS  Google Scholar 

  75. Ellerhorst JA, Sella A, Amato RJ, et al: Phase II trial of 5-fluorouracil, interferon-a and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 1997; 80:2128–2132.

    Article  PubMed  CAS  Google Scholar 

  76. Tourani J-M, Pfister C, Berdah J-F, et al: Outpatient treatment with subcutaneous interleukin-2 and interferon-a administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. J Clin Oncol 1998; 16:2505–2513.

    PubMed  CAS  Google Scholar 

  77. Ravaud A, Audhuy B, Gomez F, et al: Subcutaneous interleukin-2, interferon-a2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a mutlicenter phase II trial. J Clin Oncol 1998; 16: 2728–2732.

    PubMed  CAS  Google Scholar 

  78. Savage P, Costelna D, Moore J, Gore ME: A phase II study of continuous infusional 5-fluorouracil and subcutaneous interleukin-2 in metastatic renal cell cancer. Eur J Cancer 1996; 33:1149–1151.

    Article  Google Scholar 

  79. Joffe JK, Banks RE, Forbes MA, et al: A phase II study of interferon-a, interleukin-2 and 5fluorouracil in advanced renal carcinoma: Clinical data and laboratory evidence of protease activation. Br j Urol 1996; 77:638–649.

    Article  PubMed  CAS  Google Scholar 

  80. Negrier S, Caty A, Lesimple T, et al: Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 2000; 18:4009–4015.

    PubMed  CAS  Google Scholar 

  81. Atzpodien J, Kirchner H, Illiger HT, et al: IL-2 in combination with interferon-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br j Cancer 2001; 85:1130–1136.

    Article  PubMed  CAS  Google Scholar 

  82. Hanninen EL, Kirchner H, Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996; 155:19–25.

    Article  Google Scholar 

  83. Kirchner H, Buere J, Probst-Kepper M, et al: Risk and longer-term outcome in metastatic renal cell carcinoma patients receiving SC interleukin-2, SC interferon-af 2A, and IV 5-fluorouracil. Proc Am Soc Clin Oncol 1998; 17:310.

    Google Scholar 

  84. Dutcher JP, Atkins M, Fisher R, et al: Interleukin-2 based therapy for metastatic renal cell cancer: The Cytokine Working Group Experience, 1989–1997. Cancer J Sci Amer 1997; 3(Suppl 1): S73- S78.

    Google Scholar 

  85. Dutcher JP, Logan T, Gordon M, et al: Phase II trial of interleukin-2, interferon -a, and 5fluorouracil in metastatic renal cell cancer:A Cytokine Working Group Study. Clin Cancer Res 2000; 6:3442–3450.

    PubMed  CAS  Google Scholar 

  86. Atzpodien J, Kirchner H, Duensing S, et al: Biochemotherapy of advanced metastatic renal cell carcinoma; results of the combination of interleukin-2, a-interferon, 5-fluorouracinl, vinblastine, and 13-cis-retinoic acid. World J Urol 1995; 13:174–177.

    Article  PubMed  CAS  Google Scholar 

  87. Stadler WM, Kuzel T, Dumas M, Vogelzang NJ: Multi-center phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 1998; 16:1820–1825.

    PubMed  CAS  Google Scholar 

  88. Dutcher JP, Caliendo G, Novik Y, et al: Phase II study of moderate dose bolus or continuous infusion IL-2 plus GM-CSF in metastatic renal cell cancer. Proc Am Soc Clin Oncol 1999; 18:451a (abst 1740).

    Google Scholar 

  89. Ryan CW, Vogelzang NJ, Dumas MC, et al; Granulocyte-macrophage colony-stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: Results of two phase II clinical trials. Cancer 2000; 88:1317–1324.

    Article  PubMed  CAS  Google Scholar 

  90. Abuchowski A, McCoy JR, Palczuk NC, et al: Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977; 252:3582–3586.

    PubMed  CAS  Google Scholar 

  91. Davis S, Abuchowski A, Park YK, Davis FF: Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin Exp Immunol 1981; 46:649–652.

    PubMed  CAS  Google Scholar 

  92. Yang JC, Topalian S, Schwartzentruber DJ et al: The use of polyethylene glycol-modified interleukin2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer 1995; 687–694.

    Google Scholar 

  93. Shanafelt AB, Lin Y, Shanafelt M-C, et al: A T-cell selective interleukin-2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nature Biotechnol 2000; 18:1197–1202.

    Article  CAS  Google Scholar 

  94. Margolin KA, Atkins MB, Weber J, Dutcher JP, et al: Phase I study of interleukin-2 selective angoist BAY-50–4798 (BAY) in patients with advanced melanoma and renal cell cancer. Proc Am Soc Clin Oncol 2002; 12:10a (abst 46).

    Google Scholar 

  95. Neville ME, Boni LT, Pflug LE, et al: Biopharmaceutics of liposomal interleukin-2, oncolipin. Cytokine 2000; 12:1691–1701.

    Article  PubMed  CAS  Google Scholar 

  96. Kedar E, Gur H, Babai I, et al: Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleuin-2 encapsulated in conventional liposomes and I long-circulating liposomes. J Immunother 2000; 23:131–145.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Our Lady of Mercy Cancer Center, New York Medical College, USA

    Janice P. Dutcher M.D.

Authors
  1. Janice P. Dutcher M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of California, Los Angeles, CA, USA

    Robert A. Figlin

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dutcher, J.P. (2003). Interleukin-2 Based Therapy for Kidney Cancer. In: Figlin, R.A. (eds) Kidney Cancer. Cancer Treatment and Research, vol 116. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0451-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0451-1_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5083-5

  • Online ISBN: 978-1-4615-0451-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation